SCHEMBL131332

SCHEMBL131332

CCOC(=O)C(CC(OCC)OCC)C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
TDP1 Q9NUW8 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MMP8 P22894 1/20 0.35
TRPA1 O75762 1/20 0.34
POLB P06746 1/20 0.34
PIN1 Q13526 1/20 0.32
THRB P10828 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3687016 0.91 TDP1 (0.38) ALDH1A1LMNAHSD17B10ALOX15MGAM
Potassium Ion SCHEMBL130908 0.86 ALDH1A1 (0.33) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL3687012 0.84 MGAM (0.36) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL129216 0.83 ALDH1A1 (0.31) ALDH1A1LMNAHSD17B10TDP1MEN1
SCHEMBL4613459 0.83 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL3453810 0.82 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL9472675 0.81 THRB (0.35) ALDH1A1LMNAHSD17B10TDP1THRB
SCHEMBL30411265 0.80 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL4570452 0.78 ALDH1A1 (0.37) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL13497300 0.77 ALDH1A1 (0.36) ALDH1A1LMNAHSD17B10ALOX15MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731623-A1 CARBOLINE COMPOUNDS AND USE THEREOF PTC Therapeutics, Inc. (US) 2026-04-29 EP disclosed
WO-2025006078-A1 CARBOLINE COMPOUNDS AND USE THEREOF PTC THERAPEUTICS, INC. (US) 2025-01-02 WO disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
US-20120123119-A1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2012-05-17 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
US-8124609-B2 Acyclic nucleoside derivatives MEDIVIR AB (SE) 2012-02-28 US disclosed
US-8124609-B2 Acyclic nucleoside derivatives MEDIVIR AB (SE) 2012-02-28 US disclosed
US-20090076041-A1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2009-03-19 US disclosed
US-20090076041-A1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2009-03-19 US disclosed
CN-101374844-A Pyrrolopyridazinone compound UBE INDUSTRIES (JP) 2009-02-25 CN disclosed
US-6184376-B1 POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG MEDIVER AB (SE) 2001-02-06 US disclosed
EP-0971923-A2 SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 2000-01-19 EP disclosed
US-5869493-A ANTIVIRALS AGAINST HERPES AND RETROVIRUSES MEDIVIR AB (SE) 1999-02-09 US disclosed
EP-0888348-A1 ACYCLIC NUCLEOSIDE DERIVATIVES Medivir Aktiebolag (SE) 1999-01-07 EP disclosed
EP-0880521-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDES Medivir Aktiebolag (SE) 1998-12-02 EP disclosed
WO-1998034917-A2 SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 1998-08-13 WO disclosed
WO-1997030052-A1 SYNTHESIS OF ACYCLIC NUCLEOSIDES MEDIVIR AB (SE) 1997-08-21 WO disclosed
WO-1997030051-A1 ACYCLIC NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 1997-08-21 WO disclosed
US-4980362-A PLATELET ACTIVATING FACTOR ANTAGONISTS J. URIACH & CIA. S.A. (ES) 1990-12-25 US disclosed
EP-0381098-A2 New 4-substituted 2-alkoxytetrahydrofuran derivatives J. URIACH & CIA. S.A. (ES) 1990-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076041-A1 ACYCLIC NUCLEOSIDE DERIVATIVES NUDT1, PNP, NSUN2 ALDH1A1 2140/4885LMNA 763/4885HSD17B10 692/4885
US-20120123119-A1 ACYCLIC NUCLEOSIDE DERIVATIVES NUDT1, PNP, NSUN2 ALDH1A1 2200/4885LMNA 753/4885HSD17B10 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.